Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
University College, London
National Institutes of Health Clinical Center (CC)
RedHill Biopharma Limited
Mayo Clinic
National Cancer Institute (NCI)
La Jolla Pharmaceutical Company